.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Precision medicine continues to evolve by identifying unique vulnerabilities in tumor cells. When chromosomal deletions occur, they often remove tumor suppressor genes alongside adjacent passenger genes. This collateral loss creates a state of synthetic lethality. Specifically, the loss of FOCAD, a gene located near CDKN2A and MTAP on chromosome 9p21, induces a critical dependency on the HBS1L/PELO ribosome-rescue complex. To exploit this, researchers developed TNG961, a first-in-class HBS1L molecular glue degrader that offers a potent therapeutic strategy for these genetically defined cancers.
The HBS1L/PELO complex is vital for maintaining translational homeostasis by rescuing stalled ribosomes. In healthy cells, the SKI complex, which includes the FOCAD protein, helps manage aberrant mRNA. However, when FOCAD is deleted, the SKI complex destabilizes, leading to an accumulation of stalled ribosomes. Consequently, these cancer cells become hyper-dependent on HBS1L to survive. By using an HBS1L molecular glue degrader, clinicians can selectively induce proteasomal degradation of this essential rescue factor, leading to translational arrest and cell death.
TNG961 emerged from an intensive medicinal chemistry campaign guided by cryo-EM structures. It promotes a ternary complex between HBS1L and the E3 ligase cereblon, facilitating rapid ubiquitination. Furthermore, preclinical studies demonstrate that oral administration of TNG961 leads to significant tumor regression in various xenograft models. Notably, this HBS1L molecular glue degrader remains effective even in models that have become refractory to PRMT5 inhibitors. This finding is particularly relevant because FOCAD is co-deleted in approximately one-third of MTAP-deleted cancers, providing a secondary line of attack for difficult-to-treat malignancies.
The development of TNG961 signifies a major step forward in targeting mRNA quality control pathways. Because TNG961 is orally bioavailable and highly selective, it minimizes off-target degradation of canonical neosubstrates like IKZF1. Moreover, the high prevalence of 9p21 deletions in solid tumors, including non-small cell lung cancer (NSCLC) and pancreatic cancer, suggests a broad potential patient population. Researchers are now moving toward clinical evaluation to confirm the efficacy and safety of this first-in-class therapeutic in human subjects.
TNG961 acts as a molecular glue that brings HBS1L into proximity with the cereblon E3 ligase complex. This leads to the selective ubiquitination and subsequent proteasomal degradation of HBS1L, disrupting ribosome rescue in FOCAD-deleted cells.
FOCAD loss disrupts the SKI complex, making cells unable to process aberrant mRNA efficiently. This creates a synthetic lethal dependency on the HBS1L/PELO complex for ribosome recycling, which TNG961 exploits to kill tumor cells while sparing healthy tissue.
Yes, preclinical data show that TNG961 induces tumor regression in models that are refractory to PRMT5 inhibitors, suggesting it could be a vital treatment option for patients who have progressed on existing precision therapies.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
TNG961 is a first-in-class HBS1L molecular glue degrader designed to treat FOCAD-deleted cancers by exploiting synthetic lethal dependencies in ribosome res...
3 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
